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Abstract
Familial Danish dementia (FDD) is an autosomal dominant neurodegenerative disease
clinically characterized by the presence of cataracts, hearing impairment, cerebellar ataxia
and dementia. Neuropathologically, FDD is characterized by the presence of widespread
cerebral amyloid angiopathy (CAA), parenchymal amyloid deposition and neuroﬁbrillary
tangles. FDD is caused by a 10-nucleotide duplication-insertion in the BRI2 gene that
generates a larger-than-normal precursor protein, of which the Danish amyloid subunit
(ADan) comprises the last 34 amino acids. Here, we describe a transgenic mouse model for
FDD (Tg-FDD) in which the mouse Prnp (prion protein) promoter drives the expression of
the Danish mutant form of human BRI2. The main neuropathological ﬁndings in Tg-FDD
mice are the presence of widespread CAA and parenchymal deposition of ADan. In addi-
tion, we observe the presence of amyloid-associated gliosis, an inﬂammatory response and
deposition of oligomeric ADan. As the animals aged, they showed abnormal grooming
behavior, an arched back, and walked with a wide-based gait and shorter steps.This mouse
model may give insights on the pathogenesis of FDD and will prove useful for the develop-
ment of therapeutics. Moreover, the study ofTg-FDD mice may offer new insights into the
role of amyloid in neurodegeneration in other disorders, includingAlzheimer disease.
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INTRODUCTION
FamilialDanishdementia(FDD)wasﬁrstdescribedinmembersof
a single Danish family in the Djursland peninsula (31).The disease
was originally named heredopathia ophthalmo-oto-encephalica
because of the presence of cataracts, hearing problems and neuro-
logical disease (30, 31). Gradual loss of vision, caused by posterior
sub-capsular cataract and retinal neovascularization, seems to be
the ﬁrst symptom of the disease which starts before the age of 30.
Impaired hearing tends to appear 10–20 years later. Ataxia of a
cerebellar type starts after the age of 40. Patients develop slurred
speech as well as staggering and swaying gait. Paranoid psychosis
usually develops after the age of 50, followed by dementia. Most
patients die within the sixth and seventh decade of life (30, 31).
Neuropathologically, FDD is characterized by the presence of
cerebral amyloid angiopathy (CAA) in vessels of the retina and
leptomeninges as well as in vessels of the gray and white-matter of
the central nervous system (CNS) (15, 26, 34). Although CAA is
one of the most prominent features of the disease, the incidence of
cerebral hemorrhage is rare.All regions of the hippocampus show
extensive diffuse amyloid peptide deposition with the presence of
large (60–120 mm) cotton-wool-like plaques, abnormal neurites,
that are found in the vicinity of blood vessels with amyloid, and
neuroﬁbrillary tangles (NFTs) composed of tau paired helical ﬁla-
ments (15, 34). Western blot analysis of the insoluble tau isolated
from a patient with FDD showed a pattern similar to that seen in
cases of familial British dementia (FBD) (33) and Alzhei-
mer disease (AD) (14, 15). Molecular genetic analysis in patients
with FDD revealed the presence of a 10-nucleotide duplication
insertion (BRI2795-796InsTTTAATTTGT) in the 3’-end of the
coding region of the BRI2 gene (also known as ITM2B (7)), located
on the long arm of chromosome 13 (33, 34). The wild-type BRI2
gene encodes a 266 amino acids type-II single transmembrane
domain protein of unknown biological function (35).The mutation
in BRI2 causes a frame-shift in the BRI2 sequence, generating
the Danish amyloid precursor protein of 277 amino acids
(ADanPP), of which the ~4 kDa Danish amyloid subunit (desig-
nated ADan) comprises the last 34 amino acids (34). Furin and
othersubtilisin-likepro-proteinconvertases(PCs)(24)canprocess
both the normal and mutated precursor protein to produce the
C-terminal fragments of 23 and 34 amino acids, respectively (17,
18). In addition, all cases of FDD examined so far show the pres-
ence of amyloid b (Ab) deposited in combination with ADan or
alone in blood vessels or brain parenchyma (15, 34). The signiﬁ-
Brain Pathology ISSN 1015-6305
58 Brain Pathology 19 (2009) 58–68
© 2008 The Authors; Journal Compilation © 2008 International Society of Neuropathologycance of the co-deposition of both types of amyloid is not clear,
althoughAb has been found co-deposited with other cerebral amy-
loids such as cystatin C (37) and prion protein (3).
Herein, we report the generation and neuropathological charac-
terization of a transgenic animal model for FDD (Tg-FDD) in
which the Danish mutant form of human BRI2 is expressed under
the control of the mouse prion protein promoter. Tg-FDD mice
show signiﬁcant vascular amyloid deposition, parenchymal ADan
deposition, amyloid associated gliosis, intracellular and extracellu-
lar deposition of oligomeric forms of ADan as well as tau immu-
noreactive deposits in neuropil. Tg-FDD mice may be considered
as a new model of cerebral amyloidosis, which may be useful in
further elucidating the pathogenesis of FDD and for testing of
diagnostic and therapeutic strategies.
MATERIAL AND METHODS
Construction of the
MoPrP-BRI2795InsTTTAATTTGT transgene and
generation of transgenic mice
The 10-nucleotide duplication (TTTAATTTGT) (34) was
introduced in the BRI2 complementary DNA (cDNA) sequence
by polymerase chain reaction (PCR), and the resulting
BRI2795InsTTTAATTTGT cDNA sequence was PCR-ampliﬁed
using oligonucleotide primers containing an XhoI site, a Kozak
consensus sequence and a stop codon. The BRI2795InsTTT
AATTTGT cDNA was inserted into the previously described pBS/
MoPrP.Xho vector (2) and the orientation veriﬁed by DNA
sequencing.Theresultingconstructwaslinearizedandgel-puriﬁed
prior to injection into hybrid C3HeB/FeJ mouse embryos. Trans-
genic lines were established using standard methods at the Indiana
University Transgenic and Knock-out Mouse Core Facility. Lines
were crossed to non-transgenic C57BL/6J mice for over 10 genera-
tions and maintained by crossing transgenic animals to non-
transgenic C57BL/6J mice. For genotyping, DNA was extracted
from tail clips by proteinase K digestion followed by ethanol pre-
cipitation. The transgene was detected by PCR ampliﬁcation of a
372-basic pair (bp) product using a forward primer (5’-GAT GCC
CCA GCT GCT CTCTAC CAG-3’) and a reverse primer (5’-GTA
AGT TTC CTT GTC ATG AC-3’) located in the human BRI2
cDNA sequence (33). The care and use of animals in this study
were in accordance with institutional guidelines.
Antibodies and generation of
recombinant proteins
Polyclonal antibodies (Abs) were raised in rabbits using synthetic
peptides coupled to keyhole limpet hemocyanin through a
C-terminal Cys as immunogen. The synthetic peptides were
homologoustoresidues23–34(FNLFLNSQEKHYC)oftheADan
amyloid peptide (34) (Ab 1700) and residues 24–34 (RTVKKNI-
IEENC) of the Bri amyloid peptide (ABri) (33) (Ab 1705). The
presenceofspeciﬁcantibodieswastestedbyenzyme-linkedimmu-
nosorbent assay and dot blot analysis. Commercial polyclonalAbs
against glial ﬁbrillary acidic protein (GFAP) (Dako, Carpinteria,
CA,USA)forthedetectionofastrocytes,P-component(Dako)and
oligomer-speciﬁcantibody(A11)(Invitrogen,Carlsbad,CA,USA)
wereused,asweremonoclonalAbsagainstapolipoproteinE(ApoE)
(3D12,Accurate,Westbury, NY, USA), alpha smooth muscle actin
(1A4, Dako), microtubule associated protein tau phosphorylated at
Ser202/Thr205 (AT8, Pierce Biotechnology, Rockford, IL, USA),
keratan sulfate (5D4, Seikagaku Kogyo, Japan) for the detection of
activated microglia, DNA-binding neuron-speciﬁc protein NeuN
(A60, Chemicon, Temecula, CA, USA) and the Ab protein clone
10D5 (Elan Corporation, San Francisco, CA, USA) and clone 4G8
(SIGNET, Dedham, MA, USA). For the generation of recombinant
ADan peptides, cDNA sequences containing the coding sequences
correspondingtoaminoacids1–34oftheADanpolypeptide(ADan
1–34), 3–34 (ADan 3–34) and 1–22 (ADan 1–22) (34) were intro-
ducedintotheGlutathioneS-transferase(GST)GeneFusionVector
pGEX (GE Healthcare Bio-Sciences Corp, Piscataway, NJ, USA)
downstream from, and in frame with, the sequence encoding GST.
Recombinant polypeptides were expressed by transformed BL21
Escherichia colistrains(InvitrogenCorp,Carlsbad,CA,USA)after
induction with isopropyl-beta-D-thiogalactopyranoside (Sigma-
Aldrich, St. Louis, MO, USA). Cells were disrupted by sonication,
andsolublehomogenateswereusedforwesternblotanalysis.
Histological and immunohistochemical studies
Mice were anesthetized and transcardially perfused with cold 0.9%
saline. After perfusion, the animals were decapitated; the skulls
opened and the brains removed and kept at 4°C in 4% paraformal-
dehyde in 0.1 M phosphate buffer, pH 7.2. Eight-micrometer-thick
sections were stained with the Hematoxylin-Eosin (H&E) and
thioﬂavin S (ThS) methods. Immunohistochemical labeling was
carried out following published protocols (1). For immunohis-
tochemistry, sections were incubated overnight at 4°C with the
primary antibodies. Immunostaining was visualized using the
avidin-biotinsystem(Vectastain;VectorLaboratories,Burlingame,
CA, USA) and 3,3’-diaminobenzidine (Sigma) as the chromogen.
The sections were counterstained with cresyl violet or H&E.
Co-localization experiments were done by double-labeling immu-
noﬂuorescence. Antigen retrieval was performed in a microwave
oven in 0.01 M sodium citrate (pH 6.0). Sections were permeabi-
lized in phosphate buffered saline (PBS) containing 0.3% Triton
X-100 and unspeciﬁc binding was blocked in 10% goat serum, 2%
bovineserumalbumin,0.1%TritonX-100dilutedinPBSfor1 hat
room temperature. Primary Abs were incubated overnight at 4°C
followed by appropriate secondary antibodies conjugated with
Alexa-Fluor488 andAlexa-Fluor594 (Molecular Probes Inc, Eugene,
OR, USA). Sections were then washed three times in PBS,
mounted with ProLong anti-fade (Molecular Probes Inc) and then
viewed under a Leica DM4000B microscope with ﬂuorescence
attachment and digital camera. Fluorescence images were acquired
with a Zeiss LSM 510 confocal microscope equipped with argon
and helium/neon lasers using an inverted 63¥ NA 1.2 water-
immersion objective.
Immunoblot analysis
Brain tissue was homogenized in 10 vol of 50 mM Tris (pH 8,0),
150 mM NaCl and 5 mM EDTA containing a proteinase inhibitor
cocktail (Complete, Roche Molecular Biochemicals, Indianapolis,
IN, USA).Amyloid was extracted by incubation with 99 % formic
acid (Sigma) for 2 h at room temperature and the formic acid-
solublematerialwasdriedunderaN2atmosphereasdescribed(34).
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Tris-Tricine SDS-PAGE. Proteins were electro-transferred onto
polyvinylidene diﬂuoride membranes (Immobilon-P, Millipore
Corporation,Billerica,MA,USA)using10 mM3-cycloexylamino-
1-propanesulfonic acid buffer, pH 11, containing 10% methanol
(Sigma).Themembraneswereblockedwith5%non-fatdrymilkin
10 mM phosphate buffer, 137 mM NaCl, 2.7 mM KCl (PBS,
Sigma) pH 7.4 with 0.1% Tween-20 (PBS-T) overnight and then
incubated for 2 h at room temperature with Ab 1700. Horseradish
peroxidase-conjugated goat anti-rabbit (Amersham, Piscataway,
NJ,USA)wasusedasthesecondAbatadilutionof1:5000inPBS-T.
Immunoblots were visualized by chemiluminescence (Amersham)
accordingtothemanufacturer’sspeciﬁcations.
RESULTS
Generation of transgenic mice expressing the
Danish mutant form of BRI2 (Tg-FDD)
We generated transgenic mice by microinjecting a construct con-
taining a cDNA encoding the Danish mutant form of human BRI2
(Figure 1A) to oocytes of C3HeB/FeJ hybrids. Five independent
transgeniclineswereobtained,threeofwhichproducedstablelines
of mice that express the transgene. Expression of the transgene in
theCNSwasdrivenbythemouseprionprotein(moPrnp)promoter
(2) (Figure 1B). The presence of the transgene was conﬁrmed by
PCR ampliﬁcation of a 372-bp fragment, speciﬁc for the human
BRI2 cDNA sequence (33).All three lines developed accumulation
of amyloid in the brain with similar regional deposition and were
studied together. ADan amyloid was detectable in animals older
than 7–8 month of age by western blot analysis.ADan was present
in the formic acid soluble fraction mostly as a ~4 kDa monomer
(Figure 2A, lane 1, see arrow). ADan polymers, in particular
trimersandtetramers,werealsoseenbywesternblotanalysisusing
Ab1700.Noimmunoreactivitywasseenincontrolmice(lane2)or
usingAb 1705, against theABri peptide (not shown).The speciﬁc-
ity of Ab 1700 was conﬁrmed by western blot analysis using
recombinant proteins (Figure 2A, inset).
As the animals aged, Tg-FDD mice displayed an abnormal
grooming behavior. One-year-old transgenic mice showed an
arched back and walked with a wide-based gait and shorter steps.
Feet clasping was observed upon suspension of the mice by their
tails.Transgenic mice would ﬂex their front and hind limbs inward,
with paws clasped together and drawn in toward the body. In con-
trast, wild-type mice demonstrate normal limb posture when sus-
pended by their tails.
Vascular amyloid deposition in Tg-FDD mice
Brains from 34 heterozygous and homozygous mice and 12 age-
matched non-transgenic littermate controls (1–24 months old)
were neuropathologically examined. Between 1 and 6 months of
age, no obvious pathology was detected. At ~7 months of age,
transgenic animals consistently began to exhibit CAA primarily in
pial (leptomeningeal) cerebellar vessels. As the animals aged,
(8–9 months), large and medium-sized parenchymal and pen-
etrating vessels of the cerebrum (neocortex, hippocampus, thala-
mus and olfactory bulb), the brain stem and the spinal cord also
showed amyloid angiopathy (Figures 3–5). CAA was present in all
transgenic mice studied and amyloid deposition was seen to
increase with age.As in patients with CAA (36), individual vessels
had a varying extent of amyloid deposition, sometimes seen in the
form of focal globular clumps (Figure 3K). In the hippocampus,
vascular amyloid deposition was seen in the walls of large and
mediumsizevessels(Figure 4G,H)andinthewallofvesselsofthe
hippocampal ﬁssure (Figure 4B,N). Vessels affected by CAA
showed thickened, eosinophilic walls (Figure 4K–N). Abs against
the ADan peptide immunolabeled vascular deposits in Tg-FDD
A B
Figure 1. Amino acid sequence of ADanPP, ADan and construction of
the expression vector. A. The wild-type BRI2 polypeptide consists of 266
amino acids. The Danish BRI2 mutant polypeptide (ADanPP) has 277
amino acids. The arrow indicates the pro-protein convertase (PC) cleav-
age site that releases the ADan peptide. The putative transmembrane
domain is underlined. The ADan sequence consists of the last 34 amino
acids of the mutant protein. The sequence recognized by polyclonal
antibody 1700 is underlined. B. Expression plasmid moPrP.Xho contain-
ing a complementary DNA carrying the Danish mutant BRI2 sequence.
Black boxes, non-coding 5’ sequences; gray box, non-coding 3’
sequences; open box, Danish mutant BRI2-coding sequence.
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(Figures 3–5). Parenchymal vessels of the spinal cord that con-
tained amyloid deposits were also immunolabeled by Ab 1700.
Vascular deposits were also immunostained using Abs against
P-component (not shown) and ApoE (Figure 5F). Preliminary
attempts to identify Ab deposits were unsuccessful. Non-
transgenic littermates showed none of these neuropathological
changes.
Accumulation ofADan amyloid in vessels was accompanied by
a loss of smooth muscle cells (SMCs) in the vessel wall as shown
by the depletion of vascular SMC a-actin (Figure 2B–D) and a
decrease in the number of SMC nuclei. Vessels that were not
affected by amyloid deposition showed a continuous rim of SMCs.
Despite the massive occurrence of amyloid angiopathy inTg-FDD
mice, in none of the old mice (21 months) we analyzed did we
detect hemorrhages.
Parenchymal accumulation of ADan in
Tg-FDD mice
Parenchymal amyloid deposition was seen in brain areas affected
by CAA (Figures 3 and 4) with the exception of the cerebellum,
where it was relatively uncommon to observe the presence of ThS
ﬂuorescentmaterialthatwasnotassociatedwithvessels(Figure 5).
In the cerebral cortex we observed the presence ofThS-ﬂuorescent
deposits of ~11 mm in diameter and some small punctate deposits
of ~3 mm in diameter (Figure 3A).These deposits were immunola-
beledbyAb1700.WidespreaddiffusedepositionofADanwasalso
observedbetweenthesameregions(Figure 3C,G–I).Immunoreac-
tivity was not seen in non-transgenic littermates (Figure 3F) or
usingAb 1705 (not shown). Some of theAb 1700-immunopositive
parenchymal deposits appeared to be within oligodendrocyes
(Figure 3G–I). Double-labeling of neurons withAbs against NeuN
and Ab 1700 showed co-localization of both immunoractivities
(Figure 6). Abs against GFAP and activated microglia failed to
reveal co-localization when used in combination withAb 1700.
Parenchymal amyloid deposition was also seen throughout the
hippocampusandwasmostprominentintheCA3andCA2regions
and the hilus (Figure 4A,B). Amyloid deposits were seen as small
plaques (7–10 mm in diameter) that sometimes showed a weakThS
ﬂuorescent surrounding (Figure 4G,H) and in the form of punctate
structures (Figure 4H). Ab 1700 immunolabeled amyloid deposits
(Figure 4I,J,O,P), and also showed the presence of abundantADan
diffusedeposits(Figure 4I,J).Asinthecerebralcortex,someofthe
immunopositive deposits detected using Ab 1700 appeared to be
intracellular (Figure 4I,O,P). Furthermore, Ab 1700 revealed the
presence of diffuse parenchymal deposition of ADan in the spinal
cord (not shown). Analysis of H&E-stained sections occasionally
revealed neurons with a pyknotic appearance, in particular in corti-
cal layer II of the cerebral cortex, and neuronal shrinkage and loss
of Purkinje cells in the cerebellum. Non-transgenic littermates
showed none of these neuropathological changes.
Amyloid accumulation is associated with an
astrocytic response and microglial activation
Analysis of H&E-stained cerebral cortical sections of Tg-FDD
mice revealed the presence of a severe gliosis. Numerous GFAP-
Tg wt
4 kDa -
14 kDa -
20 kDa -
30 kDa -
45 kDa -
66 kDa -
97 kDa -
MW
A
ADan
37 kDa -
25 kDa -
MW
1-22 3-34 1-34
GST-ADan
BCD
Figure 2. ADan amyloid peptides in transgenic-Familial Danish demen-
tia (Tg-FDD) mice. A. Western blot using polyclonal antibody (Ab) 1700
(anti-ADan) of amyloid isolated from Tg-FDD mice (Tg) and wild-type
control mice (wt). ADan monomers (arrow), trimers and tetramers are
seen in the formic acid soluble fraction of Tg-FDD mice. Ab 1700 recog-
nizes recombinant ADan peptides that contain the full-length ADan
sequence (1–34) or a sequence starting at position 3 of ADan (3–34)
fused to Glutathione S-transferase (GST), but not a fusion protein con-
taining only the ﬁrst 22 amino acids of the ADan peptide (1–22) (Inset).
B–D. Laser scanning confocal microscopy of leptomeningeal vessels.
Immunolabeling for ADan (B) and vascular alpha smooth muscle actin (C)
in a meningeal vessel. Loss of smooth muscle cells in the amyloid-rich
regions of the vessel is observed in the merge image (D) in sections from
an 18-month-old homozygous Tg-FDD mouse. Immunoﬂuorescence
using Ab 1700 (B) and anti-alpha smooth muscle actin (C). Scale bar:
B–D,2 0mm.
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Figure 3. Vascular and parenchymal amyloid deposition in the cerebral
cortex. A. All cerebral cortical layers of transgenic-Familial Danish
dementia (Tg-FDD) mice show amyloid deposition and an increase in the
number of reactive astrocytes (D). Leptomeningeal and parenchymal
amyloid deposits were immunostained using polyclonal antibody (Ab)
1700 (C,G), which also stained the subpial region of the cerebral cortex.
H. Enlargement of the area indicated in (G) shows the presence of
concentrated (dot-like) and diffuse parenchymal deposits. I. High magni-
ﬁcation photograph showing parenchymal and some vascular deposits.
Amyloid deposition was seen in penetrating cortical vessels (J) and in
leptomeninges (K). L. Leptomeninges immunolabeled using Ab 1700.
Sections were from a homozygous 14 (G,H), homozygous 18 (C,I,J), and
heterozygous 21-(A,D,K,L)-month-old Tg-FDD mice and a 21-month-old
control mouse (B,E,F). Thioﬂavine-S (A,B,J,K). Immunohistochemistry
using Ab 1700 (C,F–I,L) and anti- glial ﬁbrillary acidic protein (D,E). Scale
bars: A,B,D,E, 200 mm; C,F, 100 mm; G,J–L,5 0mm; H,I,2 0mm.
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Figure 4. Vascular and parenchymal amyloid deposition in the hippoc-
ampus. Amyloid deposition is seen throughout the hippocampal forma-
tion (A,B) of transgenic-Familial Danish dementia (Tg-FDD) mice and is
accompanied by an increase in the number of reactive astrocytes (D,E).
Age-matched non-transgenic littermates showed none of these neuron-
pathological changes (C,F). Vascular amyloid deposition is present in the
walls of large and medium size vessels (A,B,G,H,M) and in the walls of
vessels of the hippocampal ﬁssure (B,N). Vessels containing amyloid
show thickened, eosinophilic walls (K,L). Thioﬂavin S ﬂuorescent small,
punctate deposits, ~3 mm in diameter, are seen in the hippocampus (H).
Anti-ADan-immunopositive structures outline the hippocampus (J),
which are either well deﬁned and plaque-like or diffuse (I,J,O). Some
polyclonal antibody (Ab) 1700-immunopositive structures appear
intracellular (I,O,P). Sections were from a homozygous 14 (G,O,P),
homozygous 18 (I,J), heterozygous 18 (K–N), and heterozygous
21-(A,B,D,E,H)-month-old Tg-FDD mice and a 21-month-old control
mouse (C,F). Thioﬂavine S (A–C,G,H,M,N). Immunohistochemistry
using Ab 1700 (I,J,O,P) and anti-glial ﬁbrillary acidic protein (D–F).
Hematoxylin-Eosin (K,L). Scale bars: A-F, 200 mm; G,H,J–L,N,5 0mm;
I,M,O,P,2 0mm.
Vidal et al Transgenic Model for FDD
63 Brain Pathology 19 (2009) 58–68
© 2008 The Authors; Journal Compilation © 2008 International Society of Neuropathologypositive reactive astrocytes were observed throughout all neocorti-
cal areas showing amyloid deposition (Figure 3D). Only a weak
astrocyte immunostaining was observed in all examined brain
regions of age-matched wild-type mice (Figure 3E). The presence
of numerous GFAP-positive reactive astrocytes was also noted in
the hippocampus of Tg-FDD mice (Figure 4D,E) but not in non-
transgenic littermates (Figure 4F). In general, activated astrocytes
in the hippocampus were seen in areas affected by ADan amyloid
deposition (Figure 7A–D) but not in areas devoid of amyloid. In
addition to astrocytes, we observed 5D4-immunopositive micro-
glia located in the close vicinity of the vascular and parenchymal
amyloid deposits. Microglial cell processes were seen surrounding
amyloid deposits (Figure 7E–H), but were not observed in associa-
tion with diffuse deposits.
Deposition of oligomeric forms of ADan and
presence of abnormal tau deposits in
Tg-FDD mice
A robust immunostaining was observed throughout the cerebrum
(Figure 8A) using Ab A11, which recognizes Ab oligomers and
oligomers of other proteins involved in neurodegenerative diseases
(16). Immunostaining was seen both intra- and extra-cellularly in
Tg-FDD mice but not in wild-type controls (Figure 8B). In the
cerebellum, Ab A11 immunostaining was seen in cell bodies
and dendrites of Purkinje cells (Figure 8C). Staining of adjacent
sections with ThS revealed lack of co-localization of A11
immunostaining and ThS ﬂuorescence, strongly suggesting that
the deposits recognized by Ab A11 represent ADan oligomers.
Immunohistochemistry using Ab AT8 revealed the presence of
numerous tau-immunopositive deposits throughout the neuropil of
the cerebral cortex and hippocampus (Figure 8D). No tangle for-
mation was seen byThS ﬂuorescence.
DISCUSSION
We generated transgenic mice expressing the Danish mutant form
ofBRI2(34).AsinFDD,CAAisoneofthemainneuropathological
ﬁndings in this model with vascular amyloid leading to a loss of
SMCs. We also observed the presence of parenchymal (mostly
diffuse) deposition ofADan and accumulation of oligomeric forms
of the peptide. SomeThS ﬂuorescent parenchymal amyloid depos-
its were also seen in the cortex and hippocampus. InTg-FDD mice,
amyloid burden appears to increase with age implying a progres-
sive ADan deposition that exceeds its clearance. As in FDD,
amyloid deposition leads to a neuroninﬂammatory response (15).
Althoughwefoundtau-positivestructures,wedidnotdetectNFTs.
Thus, Tg-FDD mice may be considered a new model of cerebral
amyloidosis.
One of the main neuropathological features of FDD is the pres-
ence of widespread CAA (15, 34). InTg-FDD mice, expression of
the Danish mutant form of BRI2 driven by the moPrnp promoter is
C
DE F
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Figure 5. Cerebellar leptomeningeal amyloid deposition. Amyloid depo-
sition is observed in pial (leptomeningeal) vessels of the cerebellum
(A,D) of transgenic-Familial Danish dementia (Tg-FDD) mice but not in
age-matched non-transgenic littermates (E). Antibodies against ADan
immunolabeled leptomeningeal and cortical blood vessels, and the
subpial region of the cerebellar cortex of Tg-FDD mice (B). No immunore-
activity is seen in non-transgenic littermates (C). F. Leptomeninges are
immunolabeled using polyclonal antibodies (Abs) against ApoE. Sections
were from a heterozygous 9 (F), homozygous 18 (A,B), and heterozy-
gous 21-(D)-month-old Tg-FDD mice and a 21-month-old control mouse
(C,E). Thioﬂavine S (A,D,E). Immunohistochemistry using Ab 1700 (B,C)
and anti-ApoE (F). Scale bars: A,B,D,E, 200 mm; C,F,5 0mm.
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plaqueshavebeenalsoobservedwhentheexpressionofthemutant
BRI2 sequence is driven by the Syrian hamster Prnp promoter (6).
Thus, the presence of CAA and the localized loss of SMCs seen in
theTg-FDD mouse model strongly suggest that neural cells are the
source of the cerebrovascular amyloid in FDD. In addition, it
denotes the vasculotropic nature of theADan peptide.The solubil-
ity properties ofADan may permit this molecule to diffuse, result-
ing in ADan being deposited around leptomeningeal vessels, as it
has been suggested forAb1-40 (38). Our data also suggest that loss
of SMCs does not require intracellularADan production and that it
may be induced in vivo by extracellular amyloid peptides, as it has
been suggested for transgenic mice models expressing mutant
forms of the amyloid b precursor protein (AbPP) (8, 13, 22, 32).
Although CAA is considered an important cause of intracerebral
hemorrhage as well as ischemic stroke (27), we have not observed
any evidence of cerebral hemorrhages in Tg-FDD mice. Alterna-
tively, vascular deposition of ADan may cause problems with the
function of affected vessels. As described by Christie et al. (5),
amyloid may interfere with the function of the vessel by: (i) pre-
senting a mechanical obstacle to vessel dilation, rendering the
vessel wall relatively rigid; (ii) causing a physical separation of
adjacent SMCs, which may disrupt contraction dependent on their
coordinated action; and (iii) having a toxic effect on SMCs that
interferewiththeabilityofthevesseltodilateappropriately.Future
in vivo and in vitro studies using cerebrovascular cells may explain
the role of ADan peptides in SMC degeneration and the possible
contribution of CAA to the pathology seen in FDD.
In theTg-FDD mouse model, the deposition of vascular amyloid
was accompanied by large increases in the number of reactive
A
D
B
C
Figure 6. Co-localization of ADan and NeuN immunoreactivities. Laser
scanning confocal microscopic analysis of cerebral cortex of an
18-month-old homozygous transgenic-Familial Danish dementia (Tg-
FDD) mouse showing the localization of polyclonal antibody 1700-
immunopositive (arrows) deposits (A) in neurons expressing the neu-
ronal marker NeuN (B). Nuclear (DAPI) staining (C) and merged image
(D). Scale bar: 20 mm.
ABCD
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Figure 7. Close association between amyloid deposits, astrocytes and
microglia. Laser scanning confocal microscopic analysis of hippocampal
sections of a homozygous 18-month-old transgenic-Familial Danish
dementia mouse showing the localization of polyclonal antibody 1700-
immunopositive deposits (A,E), glial ﬁbrillary acidic protein-positive reac-
tive astrocytes (B), keratan sulfate-positive-activated microglia (F),
nuclear (DAPI) staining (C,G) and merged images (D,H). Scale bars: A–H,
20 mm.
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with amyloid deposition has been observed in patients with FDD
(15, 29), AD (28) and in mutant AbPP transgenic mice (13, 22).
Whether the inﬂammatory response, characterized by the released
ofpotentiallyneurotoxicsubstancesandcytokines,maycauseneu-
rodegenerative changes in neurons, or may have a neuroprotective
role by stimulating the clearance of the amyloid deposits, remains
to be determined (23). Importantly, treatments designed to reduce
CAA-induced neuroinﬂammation appear to have lessened the
dementia in affected individuals (12, 25). Moreover, the reduction
of the cerebral microvascular deposition ofAb in an animal model
expressing a human Swedish/Dutch/Iowa mutant AbPP has been
shown to diminish regional neuroinﬂammation (21).
As seen in FDD patients (34),Tg-FDD mice showed presence of
abundant diffuse ADan deposits in the cerebral parenchyma. In
addition, we observed the presence of small, dot-like, ﬂuorescent
ThS structures. Larger plaque-like amyloid deposits were sporadi-
cally observed, and whether these deposits are related to blood
vessels remains to be determined. These plaque-like amyloid
deposits were seen associated with GFAP-labeled astrocytes and
activatedmicroglia.ThisﬁndingsuggeststhatADanamyloiddepo-
sition in Tg-FDD may cause the activation of an inﬂammatory
process, similarly to what has been reported in animal models of
AD (9, 11, 12, 21, 23, 25). We also found intracellular Ab 1700-
immunoreactivity in close proximity to the cell nucleus inTg-FDD
mice. This ﬁnding may reﬂect intracellular accumulation of the
amyloid peptide or the precursor protein as the residues recognized
byAb 1700 are present in both theADan peptide and theADanPP
sequences(34).ProcessingoftheprecursorproteinbyPCs(17,18)
andbyADAM10andSPPL2a/b(19)seemstobeinitiateduponthe
arrival of the protein to the Golgi (4). After processing, amino-
terminal proteolytic fragments accumulate intracellularly and the
carboxyl-terminal processing products are secreted via a regulated
secretory pathway (4). In vitro studies using transfected cell lines
have suggested that while the ABri peptide found in patients with
FBD (33) is detected both intracellularly and in the medium, the
ADan peptide accumulates predominantly in intracellular com-
partments (18). Whether intracellular accumulation of ADan pep-
tides results in neuronal dysfunction leading to neurodegeneration
remains to be seen. In contrast to Tg-FDD mice, transgenic mice
expressing a BRI2 protein–Ab42 fusion construct that generates
only Ab42 in the brain show little evidence of intraneuronal Ab
accumulation (20).
ThepresenceofADan-oligomersdetectedwithAbA11ishighly
indicative that a soluble pool (intracellular and extracellular) of
ADan may play a role in neurodegeneration. In vitro studies have
shown that fresh solutions containing soluble oligomers of ADan
are more toxic to neuronal cells than aged solutions containing
insoluble aggregates (10). Interestingly, the study ofAb oligomers
which do not co-localize with the Ab ﬁbril plaques in mouse
modelshaveshownthatAboligomerscanimpairsynapticfunction
and spatial memory and may contribute to some of the early cogni-
tivedysfunctioninAD(16).Thus,thestudyofoligomericformsof
ADaninTg-FDDmicemayallowustodeterminetheexactrolesof
intracellular and extracellular ADan peptides in neuronal toxicity
and to investigate whether similar mechanisms of toxicity exist
between FDD and AD in vivo. Our results suggest that Tg-FDD
mice may provide a unique model of cerebral amyloid deposition
that will allow drawing parallels with mouse models ofAD. More-
over, this model may provide important information on whether
amyloid peptides, regardless of their primary amino acid sequence,
share common pathogenic mechanisms.
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